Biocept, Inc. (BIOC): Price and Financial Metrics


Biocept, Inc. (BIOC): $3.91

-0.27 (-6.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BIOC POWR Grades


  • Growth is the dimension where BIOC ranks best; there it ranks ahead of 93.07% of US stocks.
  • The strongest trend for BIOC is in Momentum, which has been heading down over the past 31 weeks.
  • BIOC's current lowest rank is in the Stability metric (where it is better than 1.84% of US stocks).

BIOC Stock Summary

  • BIOC has a higher market value than only 9.56% of US stocks; more precisely, its current market capitalization is $56,022,709.
  • With a year-over-year growth in debt of 454.08%, Biocept Inc's debt growth rate surpasses 97.1% of about US stocks.
  • Revenue growth over the past 12 months for Biocept Inc comes in at 635.54%, a number that bests 98.63% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to BIOC, based on their financial statements, market capitalization, and price volatility, are GRTS, NTIP, APM, LAKE, and VIVO.
  • Visit BIOC's SEC page to see the company's official filings. To visit the company's web site, go to biocept.com.

BIOC Valuation Summary

  • In comparison to the median Healthcare stock, BIOC's price/sales ratio is 63.89% lower, now standing at 1.3.
  • Over the past 91 months, BIOC's price/earnings ratio has gone down 3.6.
  • Over the past 91 months, BIOC's price/earnings ratio has gone down 3.6.

Below are key valuation metrics over time for BIOC.

Stock Date P/S P/B P/E EV/EBIT
BIOC 2021-03-25 6.8 3.4 -2.9 -2.3
BIOC 2021-03-17 7.5 3.8 -3.2 -2.6
BIOC 2020-09-22 10.9 2.4 -2.3 -1.6
BIOC 2017-10-09 7.0 5.1 -2.0 -1.7
BIOC 2017-08-10 8.2 3.7 -2.1 -1.6
BIOC 2017-06-05 8.5 3.8 -2.2 -1.7

BIOC Growth Metrics

  • Its 5 year price growth rate is now at -99.78%.
  • Its year over year revenue growth rate is now at 635.54%.
  • The year over year price growth rate now stands at 17.36%.
BIOC's revenue has moved up $38,242,477 over the prior 15 months.

The table below shows BIOC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 43.77104 -13.66441 -6.866274
2020-12-31 27.4614 -19.7871 -17.80968
2020-09-30 10.73391 -24.15599 -25.44706
2020-06-30 5.677024 -23.04972 -26.26049
2020-03-31 5.950876 -23.08061 -27.5872
2019-12-31 5.528566 -23.04926 -25.25961

BIOC Price Target

For more insight on analysts targets of BIOC, see our BIOC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.00 Average Broker Recommendation 1.5 (Moderate Buy)

BIOC Stock Price Chart Interactive Chart >

Price chart for BIOC

BIOC Price/Volume Stats

Current price $3.91 52-week high $13.00
Prev. close $4.18 52-week low $3.46
Day low $3.90 Volume 470,300
Day high $4.19 Avg. volume 469,435
50-day MA $4.27 Dividend yield N/A
200-day MA $5.00 Market Cap 52.41M

BIOC Latest News Stream


Event/Time News Detail
Loading, please wait...

BIOC Latest Social Stream


Loading social stream, please wait...

View Full BIOC Social Stream

Latest BIOC News From Around the Web

Below are the latest news stories about Biocept Inc that investors may wish to consider to help them evaluate BIOC as an investment opportunity.

Medicare Issues Local Coverage Determination for Biocepts Target Selector Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

SAN DIEGO--(BUSINESS WIRE)-- #breastcancer--Biocept receives Medicare coverage for breast cancer assay to detect and analyze HER2 biomarker and announces CNSide and COVID-19 testing updates.

Business Wire | July 21, 2021

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

SAN DIEGO, July 21, 2021--Biocept receives Medicare coverage for breast cancer assay to detect and analyze HER2 biomarker and announces CNSide and COVID-19 testing updates.

Yahoo | July 21, 2021

Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman

SAN DIEGO--(BUSINESS WIRE)--Biocept appointed Linda Rubinstein and Antonino Morales to its Board of Directors, and named Director Samuel D. Riccitelli as Chairman of the Board.

Business Wire | July 20, 2021

Biocept to Participate in Two July Investment Conferences

SAN DIEGO, July 19, 2021--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will participate at the following investment conferences:

Yahoo | July 19, 2021

Liquid Biopsy Market Perspective, Comprehensive Analysis, Growth, Trends and Forecast 2027 | Biocept, Inc, Bio-Rad Laboratories Inc, LungLife AI, Inc, Exosome Diagnostics, F. Hoffmann-la Roche ltd

Liquid Biopsy Market study by The Insight Partners provides details about the market dynamics affecting the market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years.

OpenPR | July 12, 2021

Read More 'BIOC' Stories Here

BIOC Price Returns

1-mo -6.90%
3-mo -18.20%
6-mo -33.39%
1-year -41.34%
3-year -91.52%
5-year -99.33%
YTD -11.94%
2020 55.24%
2019 -66.74%
2018 -95.85%
2017 -10.39%
2016 -81.40%

Continue Researching BIOC

Want to see what other sources are saying about Biocept Inc's financials and stock price? Try the links below:

Biocept Inc (BIOC) Stock Price | Nasdaq
Biocept Inc (BIOC) Stock Quote, History and News - Yahoo Finance
Biocept Inc (BIOC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8385 seconds.